Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome

Inclusion Criteria: * The patient has a carcinoid syndrome defined as ≥3 stools/day and/or ≥3 flushes/week. * The patient has elevated 5-Hydroxyindoleacetic acid (above upper limit normal). * The patient has a well-differentiated mid-gut carcinoid tumour or serotonin secreting tumour of unknown localisation with hepatic metastasis. Exclusion Criteria: * The patient has undergone surgery related to a neuroendocrine tumour (NET) within 4 weeks prior to study entry or has surgery planned during the study. * The patient has received short acting somatostatin analogues (SSAs) within 2 weeks before study entry or has received short acting SSAs for more than 3 months. * The patient has received a radiolabelled SSA at any time before study entry. * The patient has received long acting SSAs under certain circumstances. * The patient has previously received any specific anti tumour treatment such as chemotherapy, (chemo)embolisation, radiotherapy or interferon in the last 6 months. * The patient has signs or symptoms of cardiac insufficiency. * The patient has an ejection fraction \<40% and/or clinically severe cardiac valvular regurgitation.